2. Gene
  3. Flt3 - Fms related receptor tyrosine kinase 3 Gene

Flt3 - Fms related receptor tyrosine kinase 3 Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：fms 相关 受体酪氨酸激酶 3

种属: Rattus norvegicus

基因 ID: 140635 | 基因类型: protein coding

关于 Flt3

Primary_assembly 12: 7,623,930-7,699,474 forward strand.mRatBN7.2:CM026985.1

This gene has 1 transcript (splice variant), 134 orthologues, 54 paralogues and is associated with 26 phenotypes. Biased expression in Spleen (RPKM 69.2), Brain (RPKM 39.3) and 7 other tissues.

功能概要

该基因编码的蛋白可启动糖皮质激素受体结合活性。参与动物器官再生；细胞对糖皮质激素刺激的反应；对有机氮化合物的反应。位于胞质溶胶中；核;和质膜。部分含蛋白质复合物。该基因的人类直系同源物与急性淋巴细胞白血病有关；急性髓性白血病；结直肠腺癌；肝细胞癌；和前列腺癌。与人类 FLT3（fms 相关受体酪氨酸激酶 3）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables Glucocorticoid Receptor binding activity. Involved in animal organ regeneration; cellular response to glucocorticoid stimulus; and response to organonitrogen compound. Located in cytosol; nucleus; and plasma membrane. Part of protein-containing complex. Human ortholog(s) of this gene implicated in acute lymphoblastic leukemia; acute myeloid leukemia; colorectal adenocarcinoma; hepatocellular carcinoma; and prostate Cancer. Orthologous to human FLT3 (fms related receptor tyrosine kinase 3). [provided by Alliance of Genome Resources, Apr 2022]

Flt3 基因产物(1)

mRNA Protein Name
NM_001100822.3 NP_001094292.1 receptor-type tyrosine-protein kinase FLT3 precursor
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables nuclear glucocorticoid receptor binding IPI
IPI: 通过物理相互作用推断
18261979 RGD
enables protein-containing complex binding IDA
IDA: 通过直接分析推断
18261979 RGD
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in animal organ regeneration IEP
IEP: 通过表达模式推断
18031378 RGD
involved in cellular response to glucocorticoid stimulus IEP
IEP: 通过表达模式推断
18261979 RGD
细胞组分 GO 注释 逻辑证据 参考文献 来源
part of protein-containing complex IDA
IDA: 通过直接分析推断
18261979 RGD
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Flt3 蛋白结构

ig

ig: pfam00047 (254 - 344)

PKc_like

PKc_like: cl21453 (571 - 948)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000 a.a.
蛋白主名 其他名称

receptor-type tyrosine-protein kinase FLT3

FL cytokine receptor

FMS-like tyrosine kinase 3

fms-related tyrosine kinase 3

相关产品

Approval
生物活性分子 (18)
目录号 产品名 作用方式
纯度 是否罕见病
HY-10201 Sorafenib Inhibitor 99.92% 是
HY-13016 Cabozantinib Inhibitor 99.96% 是
HY-12432 Gilteritinib Inhibitor 99.84% 是
HY-13001 Quizartinib Inhibitor 99.08% 是
HY-16379 Pacritinib Inhibitor 99.93% 是
HY-10201A Sorafenib tosylate Inhibitor 99.91% 是
HY-13038A Fostamatinib Inhibitor 99.50% 是
HY-112306 Ripretinib Inhibitor 98.90% 是
HY-10201S Sorafenib-d3 Inhibitor 99.57% 否
HY-12432A Gilteritinib hemifumarate Inhibitor 99.75% 是
HY-50867 Lestaurtinib Inhibitor 99.17% 否
HY-13038 Fostamatinib Disodium Inhibitor 99.88% 是
HY-13038B Fostamatinib disodium hexahydrate Inhibitor 99.73% 是
HY-14217 Quizartinib dihydrochloride Inhibitor 99.81% 是
HY-10201R Sorafenib (Standard) Inhibitor 99.71% 否
HY-12432R Gilteritinib (Standard) Inhibitor / 否
HY-13016A Cabozantinib hydrochloride Inhibitor / 否
HY-10201AR Sorafenib (tosylate) (Standard) Inhibitor / 否
Clinical Phase
生物活性分子 (36)
目录号 产品名 作用方式
纯度 Phase
HY-50751 Linifanib Inhibitor 99.28% Phase 3
HY-50514 AT9283 Inhibitor 99.67% Phase 3
HY-16961 Sitravatinib Inhibitor 99.57% Phase 3
HY-50905 Dovitinib Inhibitor 99.88% Phase 3
HY-10207 Dovitinib lactate Inhibitor 99.75% Phase 3
HY-16961A Sitravatinib malate Inhibitor / Phase 3
HY-B0062 Dovitinib lactate hydrate Inhibitor / Phase 3
HY-16379B Pacritinib citrate Inhibitor / Phase 3
HY-13024 Rebastinib Inhibitor 99.91% Phase 2
HY-135317 Emavusertib Inhibitor 99.96% Phase 2
HY-15514 Merestinib Inhibitor 99.99% Phase 2
HY-13034 Gandotinib Inhibitor 99.86% Phase 2
HY-101549 MRX-2843 Inhibitor 99.70% Phase 2
HY-10206 Amuvatinib Inhibitor 99.47% Phase 2
HY-100867A Mivavotinib monohydrochloride Inhibitor 99.91% Phase 2
HY-10987A ENMD-2076 Inhibitor 99.99% Phase 2
HY-145015 Tuspetinib 99.85% Phase 2
HY-10202 Tandutinib Inhibitor 99.48% Phase 2
HY-130247 Flonoltinib Inhibitor 99.79% Phase 2
HY-10987 ENMD-2076 Tartrate Inhibitor 99.42% Phase 2
HY-10202A Tandutinib hydrochloride Inhibitor 99.78% Phase 2
HY-15514A Merestinib dihydrochloride Inhibitor 99.36% Phase 2
HY-118304B AKN-028 acetate Inhibitor 99.95% Phase 2
HY-130247A Flonoltinib TFA Inhibitor 99.77% Phase 2
HY-100867 Mivavotinib Inhibitor / Phase 2
HY-135317B Emavusertib hydrochloride Inhibitor / Phase 2
HY-10058 AT9283 lactic acid Inhibitor / Phase 2
HY-118304 AKN-028 Inhibitor / Phase 2
HY-10206A Amuvatinib hydrochloride Inhibitor / Phase 2
HY-10339 KW-2449 Inhibitor 99.69% Phase 1
HY-B0791 Altiratinib Inhibitor 98.05% Phase 1
HY-111361 FN-1501 Inhibitor 99.08% Phase 1
HY-13072 Cenisertib Inhibitor 99.86% Phase 1
HY-139535 Luxeptinib Inhibitor 99.30% Phase 1
HY-13223A Crenolanib benzenesulfonate Inhibitor / Phase 1
HY-118084 LS-104 Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (170)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-12067 R406 Inhibitor 96.70% 否
HY-13223 Crenolanib Inhibitor 99.68% 是
HY-12344 UNC2025 Inhibitor 99.83% 否
HY-13263 CHIR-124 Inhibitor 99.05% 否
HY-15166 (E/Z)-Zotiraciclib Inhibitor 99.96% 否
HY-153886 Wu-5 Inhibitor 99.34% 否
HY-11108 R406 free base Inhibitor 99.80% 否
HY-15002 AST 487 Inhibitor 98.90% 否
HY-12461 WS6 Modulator 99.94% 否
HY-10032 PF 477736 Inhibitor 99.21% 否
HY-12344A UNC2025 hydrochloride Inhibitor 99.87% 否
HY-132166 M4205 Inhibitor 99.47% 否
HY-10410 TG101209 Inhibitor 99.22% 否
HY-132200 UNC5293 Inhibitor 99.93% 否
HY-N0071 Crotonoside Inhibitor 99.64% 否
HY-13894 Tyrphostin AG1296 Inhibitor 99.69% 否
HY-P5438 Srctide Substrate 99.93% 否
HY-145723 MAX-40279 Inhibitor 97.04% 否
HY-15889 AMG 925 Inhibitor 98.20% 否
HY-15003 ATH686 Inhibitor 99.54% 否
HY-153857 Lasmotinib Inhibitor 98.97% 否
HY-120758 SEL24-B489 Inhibitor 99.02% 否
HY-12333 Denfivontinib Inhibitor ≥98.0% 否
HY-12420 JNJ-47117096 hydrochloride Inhibitor 99.68% 否
HY-120590 Ruserontinib Inhibitor 99.82% 否
HY-15166B (E/Z)-Zotiraciclib citrate Inhibitor 98.06% 否
HY-18952A (Z)-SU5614 Inhibitor 98.09% 否
HY-114323 PROTAC FLT-3 degrader 1 Inhibitor 99.74% 否
HY-15166A (E/Z)-Zotiraciclib hydrochloride Inhibitor 99.90% 否
HY-13907 TCS 359 Inhibitor 99.89% 否
HY-13016S Cabozantinib-d6 Inhibitor 98.14% 否
HY-112145 FLT3-IN-3 Inhibitor 99.95% 否
HY-131906 JAK2-IN-7 Inhibitor 99.15% 否
HY-110293 CHMFL-FLT3-122 Inhibitor 98.47% 否
HY-18744 FLT3-IN-2 Inhibitor 98.80% 否
HY-124502 UNC4203 Inhibitor 99.80% 否
HY-148070 FLT3-IN-17 Inhibitor 99.56% 否
HY-18179 AZD2932 Inhibitor 99.04% 否
HY-13493 AC710 Inhibitor 99.13% 否
HY-18161 CCT241736 Inhibitor 99.88% 否
HY-162037 CDDD11-8 Inhibitor 99.62% 否
HY-132150A HPK1-IN-2 dihydrochloride Inhibitor 98.69% 否
HY-151904 AXL-IN-13 98.03% 否
HY-12960 SKLB4771 Inhibitor 99.20% 否
HY-128571 FLT3-IN-4 Inhibitor 99.73% 否
HY-12432S1 Gilteritinib-d8 Inhibitor ≥98.0% 否
HY-19897 4SC-203 Inhibitor 98.98% 否
HY-110026 GTP-14564 Inhibitor 99.91% 否
HY-107417 Hypothemycin Inhibitor ≥98.0% 否
HY-144869 OTS447 Inhibitor 99.83% 否
HY-145723C MAX-40279 hemiadipate Inhibitor 99.26% 否
HY-15496 E6201 Inhibitor / 否
HY-128572 FLT3-IN-6 Inhibitor 99.14% 否
HY-100865 BPR1K871 Inhibitor 99.12% 否
HY-15889A AMG 925 (HCl) Inhibitor / 否
HY-153473 FLT3-IN-19 Inhibitor 99.19% 否
HY-134481 FLT3-IN-10 Inhibitor 98.80% 否
HY-13537A BPR1J-097 Hydrochloride Inhibitor 99.20% 否
HY-148036 FLT3-IN-16 Inhibitor 98.98% 否
HY-143286A PF15 TFA Degrader 99.72% 否
HY-13537 BPR1J-097 Inhibitor / 否
HY-15198 KG5 Inhibitor 99.79% 否
HY-108263 3-Hydroxy Midostaurin Inhibitor 97.02% 否
HY-155195 FLT3/CHK1-IN-1 Inhibitor 98.00% 否
HY-130247C Flonoltinib sulfate Inhibitor / 否
HY-145723B MAX-40279 hemifumarate Inhibitor 99.56% 否
HY-146749 FLT3/TrKA-IN-1 Inhibitor / 否
HY-145015A Tuspetinib hydrate Inhibitor / 否
HY-145723A MAX-40279 hydrochloride Inhibitor / 否
HY-112475 Flt-3 Inhibitor III Inhibitor / 否
HY-168115 Multi-kinase inhibitor 4 Inhibitor / 否
HY-151961 RSH-7 Inhibitor 99.07% 否
HY-146680 FLT3/ITD-IN-4 Inhibitor / 否
HY-169076 FLT3/HDAC-IN-1 Inhibitor / 否
HY-144777 FLT3-IN-14 Inhibitor / 否
HY-145902 PDGFRα/FLT3-ITD-IN-1 Inhibitor / 否
HY-13016S1 Cabozantinib-d4 Inhibitor / 否
HY-151945 TRK II-IN-1 Inhibitor / 否
HY-157213 LWY713 Degrader / 否
HY-159953 IRAK1/4/pan-FLT3 Kinase-IN-1 Inhibitor / 否
HY-139996 Pomalidomide-C5-Dovitinib Inhibitor / 否
HY-162906 FLT3/HDAC-IN-2 Inhibitor / 否
HY-112378 D-65476 Inhibitor / 否
HY-170640 FLT3-IN-29 Inhibitor / 否
HY-162032 FLT3-IN-25 Inhibitor / 否
HY-171146 HSN748 Inhibitor / 否
HY-163068 FLT3-IN-24 Inhibitor / 否
HY-170769 FLT3 Ligand-Linker Conjugate 1 Inhibitor / 否
HY-143894 FLT3-IN-11 Inhibitor / 否
HY-145690 HP1328 Inhibitor / 否
HY-111249 TTT 3002 Inhibitor / 否
HY-148522 FLT3-IN-18 Inhibitor / 否
HY-161280 PROTAC FLT-3 degrader 3 Degrader / 否
HY-145691 HP1142 Inhibitor / 否
HY-15163A Zotiraciclib hydrochloride Inhibitor / 否
HY-161709 FLT3/CDKs ligand-1 Degrader / 否
HY-108263S 3-Hydroxy Midostaurin-d5 Inhibitor / 否
HY-139619 LT-850-166 Inhibitor / 否
HY-162936 SILA-123 Inhibitor / 否
HY-143278 FLT3-IN-13 Inhibitor / 否
HY-103464 5'-Fluoroindirubinoxime Inhibitor ≥98.0% 否
HY-155594 LT-540-717 Inhibitor / 否
HY-170846 FGFRs-IN-1 Inhibitor / 否
HY-168982 Lomonitinib Inhibitor / 否
HY-155112 Antiproliferative agent-30 Inhibitor / 否
HY-149539 PLM-101 Inhibitor / 否
HY-115904 FLT3/CDK4-IN-1 Inhibitor / 否
HY-15519 LBW242 Inhibitor / 否
HY-125051 SG3-179 Inhibitor / 否
HY-170576 FLT3-IN-28 Inhibitor / 否
HY-144709 FLT3/ITD-IN-1 Inhibitor / 否
HY-108263B (R)-3-Hydroxy Midostaurin Inhibitor / 否
HY-143286 PF15 Inhibitor / 否
HY-144710 FLT3/ITD-IN-2 Inhibitor / 否
HY-149474 HDAC-IN-63 Inhibitor / 否
HY-123237 KRC-108 Inhibitor / 否
HY-143895 FLT3-IN-12 Inhibitor / 否
HY-50905S Dovitinib-d8 Inhibitor / 否
HY-158265 FLT3D835Y/F691L-IN-1 Inhibitor / 否
HY-10201S1 Sorafenib-d4 Inhibitor / 否
HY-170689 CG-3-246 Inhibitor / 否
HY-161708 PROTAC FLT3/CDKs degrader-1 Degrader / 否
HY-150582 c-Met-IN-14 Inhibitor / 否
HY-108263A (S)-3-Hydroxy Midostaurin Inhibitor / 否
HY-126920 AFG206 Inhibitor / 否
HY-160848 FLT3/ITD-IN-5 Inhibitor / 否
HY-156410 FLT3-IN-23 Inhibitor / 否
HY-112417 Ki11502 Inhibitor 99.30% 否
HY-143434 FLT3/D835Y-IN-1 Inhibitor / 否
HY-168493 FLT3/VEGFR2-IN-1 Inhibitor / 否
HY-168114 Multi-kinase inhibitor 3 Inhibitor / 否
HY-145904 PDGFRα/FLT3-ITD-IN-3 Inhibitor / 否
HY-115906 K783-0308 Inhibitor / 否
HY-155770 FLT3-IN-20 Inhibitor / 否
HY-162367 FLT3/CHK1-IN-2 Inhibitor / 否
HY-170558 FW-1 Inhibitor / 否
HY-144711 FLT3/ITD-IN-3 Inhibitor / 否
HY-158325 PROTAC FLT-3 degrader 4 Inhibitor / 否
HY-146886 FLT3-IN-15 Inhibitor / 否
HY-18949 JI6 Inhibitor / 否
HY-145903 PDGFRα/FLT3-ITD-IN-2 Inhibitor / 否
HY-155226 FLT3-IN-21 Inhibitor / 否
HY-155302 FLT3-IN-22 Inhibitor / 否
HY-161323 FLT3-ITD/D835Y-IN-1 Inhibitor / 否
HY-155341 HSK205 Inhibitor / 否
HY-10201S2 Sorafenib-13C,d3 Inhibitor 98.35% 否
HY-148521 PROTAC FLT3/CDK9 degrader-1 Degrader / 否
HY-161967 JAK2/FLT3-IN-3 Inhibitor / 否
HY-168741 FLT3-ITD-IN-2 Inhibitor / 否
HY-123201 KRN383 analog Inhibitor / 否
HY-148036S FLT3-IN-16-d1 Inhibitor / 否
HY-116129 BPR1J-340 Inhibitor / 否
HY-168213 FLT3-IN-27 Inhibitor / 否
HY-118304A AKN-028 TFA Inhibitor / 否
HY-10202B Tandutinib sulfate Inhibitor / 否
HY-160787 NCGC1481 Inhibitor / 否
HY-135317E Emavusertib maleate Inhibitor / 否
HY-50751S Linifanib-d4 Inhibitor / 否
HY-13072B Cenisertib benzoate Inhibitor / 否
HY-12420A JNJ-47117096 Inhibitor / 否
HY-122240 AAE871 Inhibitor / 否
HY-135317F Emavusertib phosphate Inhibitor / 否
HY-130247B Flonoltinib monomaleate Inhibitor / 否
HY-135317D Emavusertib mesylate Inhibitor / 否
HY-135317C Emavusertib tosylate Inhibitor / 否
HY-10201S4 Sorafenib-d3 tosylate Inhibitor / 否
HY-112350 AGL 2043 Inhibitor / 否
HY-101549A MRX-2843 hydrochloride Inhibitor / 否
HY-15163 Zotiraciclib Inhibitor / 否
HY-111545 BSc5371 Inhibitor / 否
抗体抑制剂 (2)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99916 Emirodatamab / 否
HY-P990786 Anti-FLT3 Antibody (AGS62P) Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Flt3 NCBI NCBI:2322
Macaca fascicularis Flt3 NCBI NCBI:102144988
Mus musculus Flt3 NCBI NCBI:14255
Susscrofa domestica Flt3 NCBI
Macaca mulatta Flt3 NCBI NCBI:721712
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z